NetworkNewsBreaks – Why Processa Pharmaceuticals
Post# of 40
(Total Views: 208)
Posted On: 11/02/2020 2:42:09 PM
NetworkNewsBreaks – Why Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Is ‘One to Watch’
Processa Pharmaceuticals (NASDAQ: PCSA) is a clinical-stage biopharmaceutical company focused on the development of drug products for patients with high unmet medical need conditions or no alternative treatment options. A recent article discussing the company reads, “Headquartered in Hanover, Maryland, Processa has built a pipeline of drugs, which already have proof-of-concept data supporting clinical use in their selected indications. The Processa process focuses on the advancement of drugs that are ready for clinical development or have minimal pre-IND enabling studies to complete. More specifically, Processa: acquires drugs that already have some clinical data to support the targeted treatment; navigates through the FDA, collaborating with the reviewers to define a complete development program; and develops each drug over the course of 2-5 years, out-licensing either just prior to pivotal study, after Phase 2b or after the completion of the pivotal study.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Processa Pharmaceuticals (NASDAQ: PCSA) is a clinical-stage biopharmaceutical company focused on the development of drug products for patients with high unmet medical need conditions or no alternative treatment options. A recent article discussing the company reads, “Headquartered in Hanover, Maryland, Processa has built a pipeline of drugs, which already have proof-of-concept data supporting clinical use in their selected indications. The Processa process focuses on the advancement of drugs that are ready for clinical development or have minimal pre-IND enabling studies to complete. More specifically, Processa: acquires drugs that already have some clinical data to support the targeted treatment; navigates through the FDA, collaborating with the reviewers to define a complete development program; and develops each drug over the course of 2-5 years, out-licensing either just prior to pivotal study, after Phase 2b or after the completion of the pivotal study.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Processa Pharmaceuticals, Inc. (PCSA) Stock Research Links
Scroll down for more posts ▼